“UGN-101… has the potential to change practice for patients with low-grade renal pelvis cancer,” says researcher John L. Gore, MD.
AUA Annual Meeting
Researchers found that 30 of 46 study participants (65%) experienced more than a 50% improvement in urgency urinary incontinence with the nickel-sized device.
Increasing the frequency setting on a holmium:YAG laser increases stone fragmentation, but determining the saturation point at which efficiency plateaus requires further study.
The majority of medication prescribed to patients undergoing outpatient urologic procedures goes unused, prospective data reveal.
An analysis of Medicare expenditures in the first year after a diagnosis of prostate cancer shows that 5% of patients account for almost 25% of the total spending.
The use of enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA) show differences in overall survival and health care costs when used to treat chemotherapy-naïve metastatic castrate-resistant prostate cancer.
With the AUA annual meeting quickly approaching, Victor W. Nitti, MD, chair of the AUA Office of Education, provides a snapshot of new course offerings and other AUA educational opportunities.
In advance of this year’s AUA annual meeting, Urology Times asked members of our editorial board to choose the top presentations in their subspecialty.
Ray Painter, MD, and Mark Painter also answer coding questions regarding vasectomy and code 50543.
Men with large prostates experience more relief from BPH with treatment by Aquablation therapy (using the AquaBeam System) than with transurethral resection of the prostate, researchers say.